MET and non-small cell lung carcinoma: In order to assess the utility of this system for analysis of targeted therapies, we subjected two established non-small cell lung cancer cell lines H522 and H3122 to crizotinib treatment, a tyrosine kinase inhibitor (TKI) with activity against ALK, ROS1 and CMET [21–23].